0000000000264329

AUTHOR

Thomas Filleron

0000-0003-0724-0659

showing 2 related works from this author

DNA polymeraseθ up-regulation is associated with poor survival in breast cancer, perturbs DNA replication, and promotes genetic instability

2010

“Replicative stress” is one of the main factors underlying neoplasia from its early stages. Genes involved in DNA synthesis may therefore represent an underexplored source of potential prognostic markers for cancer. To this aim, we generated gene expression profiles from two independent cohorts (France,n= 206; United Kingdom,n= 117) of patients with previously untreated primary breast cancers. We report here that among the 13 human nuclear DNA polymerase genes, DNA Polymerase θ (POLQ) is the only one significantly up-regulated in breast cancer compared with normal breast tissues. Importantly,POLQup-regulation significantly correlates with poor clinical outcome (4.3-fold increased risk of de…

DNA ReplicationGenome instabilityDNA damageDNA polymerase[SDV]Life Sciences [q-bio]DNA Polymerase ThetaBreast NeoplasmsDNA-Directed DNA PolymeraseKaplan-Meier Estimatemedicine.disease_causeBioinformaticsGenomic InstabilityCell LineCohort Studies03 medical and health sciences0302 clinical medicineBreast cancerCell Line TumorChromosome instabilityCyclin EmedicineHumansComputingMilieux_MISCELLANEOUS030304 developmental biology0303 health sciencesMultidisciplinarybiologyReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingCancerMiddle AgedBiological SciencesPrognosismedicine.diseaseUnited KingdomUp-RegulationGene Expression Regulation Neoplastic030220 oncology & carcinogenesisCancer researchbiology.proteinFemaleRNA InterferenceFranceCarcinogenesisDNA DamageProceedings of the National Academy of Sciences
researchProduct

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (…

2015

ABSTRACT The DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) aims to provide recommendations for definitions of time-to-event end points in cancer randomized controlled trials. We relied on a consensus method based on a multidisciplinary panel of experts to develop these guidelines for trials on sarcomas and gastrointestinal stromal tumors. Background The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-event (TTE) end points is rarely precise and lacks unif…

medicine.medical_specialtyConsensusTime FactorssarcomaDelphi TechniqueEndpoint Determination[SDV]Life Sciences [q-bio]Disease-Free Survivallaw.invention03 medical and health sciencesgastrointestinal stromal tumors0302 clinical medicineRandomized controlled trialSDG 3 - Good Health and Well-beinglawMultidisciplinary approachTerminology as TopicmedicineHumansMedical physicsTreatment Failureguidelinestime-to-event end pointComputingMilieux_MISCELLANEOUSRandomized Controlled Trials as Topic030304 developmental biologyEvent (probability theory)0303 health sciencesEnd pointGiSTSurrogate endpointbusiness.industryefficacy measureCancerHematologymedicine.disease3. Good healthOncologyResearch Design030220 oncology & carcinogenesisrandomized controlled trialDisease ProgressionRadiologySarcomabusiness
researchProduct